Use of magnesium sulfate before 32 weeks of gestation : A European population-based cohort study

Autor: Wolf, H. T., Huusom, L., Weber, T., Piedvache, A., Schmidt, S., Norman, M., Zeitlin, J., Martens, E., Martens, G., Van Reempts, P., Boerch, K., Hasselager, A., Pryds, O., Toome, L., Varendi, H., Ancel, P. Y., Blondel, B., Burguet, A., Jarreau, P. H., Truffert, P., Maier, R. F., Misselwitz, B., Gortner, L., Baronciani, D., Gargano, G., Agostino, R., DiLallo, D., Franco, F., Carnielli, V., Cuttini, M., Koopman-Esseboom, C., Van Heijst, A., Nijman, J., Gadzinowski, J., Mazela, J., Graça, L. M., MacHado, M. C., Rodrigues, C., Rodrigues, T., Barros, H., Bonamy, A. K., Wilson, E., Boyle, E., Draper, E. S., Manktelow, B. N., Fenton, A. C., Milligan, D. W A, Bonet, M.
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Severity of Illness Index
Cohort Studies
0302 clinical medicine
PREVENTIVE MEDICINE
Pre-Eclampsia
Pregnancy
Obstetrics and Gynaecology
Eclampsia
030212 general & internal medicine
Practice Patterns
Physicians'
reproductive and urinary physiology
Medicine(all)
education.field_of_study
030219 obstetrics & reproductive medicine
Evidence-Based Medicine
Obstetrics
Medical record
General Medicine
Calcium Channel Blockers
female genital diseases and pregnancy complications
3. Good health
Europe
Pregnancy Trimester
Second
embryonic structures
Population study
Gestation
Premature Birth
Female
Guideline Adherence
Cohort study
Adult
medicine.medical_specialty
HELLP Syndrome
Population
Gestational Age
03 medical and health sciences
Magnesium Sulfate
Young Adult
Intensive care
medicine
Journal Article
Humans
education
Fetus
business.industry
Research
fungi
medicine.disease
equipment and supplies
business
Zdroj: BMJ open [E], 7(1). BMJ Publishing Group
BMJ Open
Wolf, H T, Weber, T, Piedvache, A, Schmidt, S, Norman, M, Zeitlin, J, The EPICE Research Group, Martens, E, Martens, G, Van Reempts, P, Boerch, K, Hasselager, A, Huusom, L, Pryds, O, Weber, T, Toome, L, Varendi, H, Ancel, P Y, Blondel, B, Burguet, A, Jarreau, P H, Truffert, P, Maier, R F, Misselwitz, B, Schmidt, S, Gortner, L, Baronciani, D, Gargano, G, Agostino, R, DiLallo, D, Franco, F, Carnielli, V, Cuttini, M, Koopman-Esseboom, C, Van Heijst, A, Nijman, J, Gadzinowski, J, Mazela, J, Graça, L M, MacHado, M C, Rodrigues, C, Rodrigues, T, Barros, H, Bonamy, A K, Norman, M, Wilson, E, Boyle, E, Draper, E S, Manktelow, B N & Fenton, A C 2017, ' Use of magnesium sulfate before 32 weeks of gestation : A European population-based cohort study ', BMJ Open, vol. 7, e013952 . https://doi.org/10.1136/bmjopen-2016-013952
ISSN: 2044-6055
Popis: Objectives: The use of magnesium sulfate (MgSO4) in European obstetric units is unknown. We aimed to describe reported policies and actual use of MgSO4 in women delivering before 32 weeks of gestation by indication. Methods: We used data from the European Perinatal Intensive Care in Europe (EPICE) population-based cohort study of births before 32 weeks of gestation in 19 regions in 11 European countries. Data were collected from April 2011 to September 2012 from medical records and questionnaires. The study population comprised 720 women with severe preeclampsia, eclampsia or HELLP and 3658 without preeclampsia delivering from 24 to 31 weeks of gestation in 119 maternity units with 20 or more very preterm deliveries per year. Results: Among women with severe pre-eclampsia, eclampsia or HELLP, 255 (35.4%) received MgSO4 before delivery. 41% of units reported use of MgSO4 whenever possible for pre-eclampsia and administered MgSO4 more often than units reporting use sometimes. In women without pre-eclampsia, 95 (2.6%) received MgSO4. 9 units (7.6%) reported using MgSO4 for fetal neuroprotection whenever possible. In these units, the median rate of MgSO4 use for deliveries without severe pre-eclampsia, eclampsia and HELLP was 14.3%. Only 1 unit reported using MgSO4 as a first-line tocolytic. Among women without preeclampsia, MgSO4 use was not higher in women hospitalised before delivery for preterm labour. Conclusions: Severe pre-eclampsia, eclampsia or HELLP are not treated with MgSO4 as frequently as evidence-based medicine recommends. MgSO4 is seldom used for fetal neuroprotection, and is no longer used for tocolysis. To continuously lower morbidity, greater attention to use of MgSO4 is needed.
Databáze: OpenAIRE
Externí odkaz: